IMVT
Immunovant, Inc. [IMVT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMVT Stock Summary
Top 10 Correlated ETFs
IMVT
Top 10 Correlated Stocks
IMVT
In the News
IMVT Financial details
Company Rating
Neutral
Market Cap
4.26B
Income
-243.45M
Revenue
0
Book val./share
4.7
Cash/share
4.78
Dividend
-
Dividend %
-
Employees
164
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-22.5
Forward P/E
-
PEG
-7.85
P/S
-
P/B
22.81
P/C
5.82
P/FCF
-30.19
Quick Ratio
6.74
Current Ratio
7.23
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-1.84
EPS next Y
-
EPS next Q
-
EPS this Y
19.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20%
-
-
-
-
SMA20
-6.45%
SMA50
-19.44%
SMA100
-14.71%
Inst Own
37.99%
Inst Trans
0.84%
ROA
-87%
ROE
-77%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
14.11-45.58
52W High
-38.2%
52W Low
+98.64%
RSI
34
Rel Volume
0.64
Avg Volume
1.14M
Volume
733.38K
Perf Week
-9.47%
Perf Month
-12.24%
Perf Quarter
-16.79%
Perf Half Y
-25.68%
-
-
-
-
Beta
0.697
-
-
Volatility
0.99%, 1.26%
Prev Close
-1.8%
Price
27.81
Change
-1.42%
IMVT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2018-12-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.29 | -1.54 | -1.22 | -1.43 | -1.71 | |
| Operating cash flow per share | -1.29 | -1.24 | -0.95 | -0.97 | -1.53 | |
| Free cash flow per share | -1.29 | -1.24 | -0.95 | -0.97 | -1.53 | |
| Cash per share | 14.66 | 2.33 | 4.56 | 4.5 | 3.06 | |
| Book value per share | 1.11 | 2.18 | 4.46 | 4.28 | 2.95 | |
| Tangible book value per share | 1.11 | 2.18 | 4.46 | 4.28 | 2.95 | |
| Share holders equity per share | 1.11 | 2.18 | 4.46 | 4.28 | 2.95 | |
| Interest debt per share | 13.53 | 0.09 | 0.04 | 0.03 | 0.11 | |
| Market cap | 220.59K | 672.61M | 1.41B | 604.33M | 1.91B | |
| Enterprise value | 195.59K | 575.23M | 1.01B | 112.88M | 1.53B | |
| P/E ratio | -7.71 | -10.13 | -13.1 | -3.86 | -9.05 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -7.73 | -12.61 | -16.89 | -5.7 | -10.14 | |
| PFCF ratio | -7.71 | -12.6 | -16.85 | -5.68 | -10.13 | |
| P/B Ratio | 8.98 | 7.15 | 3.6 | 1.29 | 5.27 | |
| PTB ratio | 8.98 | 7.15 | 3.6 | 1.29 | 5.27 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -6.88 | -8.76 | -9.38 | -0.72 | -7.73 | |
| EV to operating cash flow | -6.85 | -10.78 | -12.13 | -1.06 | -8.15 | |
| EV to free cash flow | -6.84 | -10.77 | -12.1 | -1.06 | -8.14 | |
| Earnings yield | -0.13 | -0.1 | -0.08 | -0.26 | -0.11 | |
| Free cash flow yield | -0.13 | -0.08 | -0.06 | -0.18 | -0.1 | |
| Debt to equity | 12.22 | 0.03 | 0.01 | 0.01 | 0 | |
| Debt to assets | 0.74 | 0.03 | 0.01 | 0 | 0 | |
| Net debt to EBITDA | 0.88 | 1.48 | 3.68 | 3.15 | 1.89 | |
| Current ratio | 0.85 | 7.12 | 21.79 | 11.52 | 9.34 | |
| Interest coverage | 0 | -105.07 | 0 | -238.41 | -15.9 | |
| Income quality | 1 | 0.8 | 0.78 | 0.68 | 0.89 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -5.2 | -1.48 | -3.23 | -2.02 | -1.02 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.67 | 8.68 | 11.08 | 11.74 | 10.66 | |
| ROIC | -0.09 | -0.68 | -0.27 | -0.33 | -0.54 | |
| Return on tangible assets | -0.07 | -0.61 | -0.26 | -0.3 | -0.52 | |
| Graham Net | -2.5 | 2.03 | 4.33 | 4.17 | 2.71 | |
| Working capital | -55.45K | 93.76M | 390.24M | 468.41M | 361.04M | |
| Tangible asset value | 24.55K | 94.07M | 391.48M | 469.83M | 362.49M | |
| Net current asset value | -55.45K | 93.76M | 388M | 467.19M | 360.99M | |
| Invested capital | 12.22 | 0.03 | 0.01 | 0.01 | 0 | |
| Average receivables | 0 | 1.52M | 1.8M | 6.7M | 6.87M | |
| Average payables | 0 | 595.1K | 1.81M | 10.53M | 9.99M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 20.68K | 889.46 | 5.52K | 372.99 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.02 | 0.41 | 0.07 | 0.98 | |
| Inventory turnover | 0 | 0 | 17145509.45B | 21165598.83B | 22746146.8B | |
| ROE | -1.16 | -0.71 | -0.27 | -0.33 | -0.58 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.49 | -0.46 | -0.57 | -0.45 | -0.36 | |
| Operating cash flow per share | -0.36 | -0.43 | -0.36 | -0.46 | -0.33 | |
| Free cash flow per share | -0.36 | -0.43 | -0.36 | -0.46 | -0.33 | |
| Cash per share | 3.36 | 2.9 | 2.53 | 2.06 | 4.78 | |
| Book value per share | 3.23 | 2.8 | 2.3 | 1.92 | 4.7 | |
| Tangible book value per share | 3.23 | 2.8 | 2.3 | 1.92 | 4.7 | |
| Share holders equity per share | 3.23 | 2.8 | 2.3 | 1.92 | 4.7 | |
| Interest debt per share | 0.03 | -0.02 | 0.01 | 0 | 0 | |
| Market cap | 2.28B | 2.01B | 2.48B | 5.04B | 6.09B | |
| Enterprise value | 1.85B | 1.64B | 2.15B | 4.77B | 5.4B | |
| P/E ratio | -9.02 | -8.46 | -8.37 | -21.46 | -29.6 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -49.19 | -36.04 | -52.26 | -83.83 | -129.28 | |
| PFCF ratio | -49.09 | -36.02 | -52.21 | -83.79 | -128.92 | |
| P/B Ratio | 5.5 | 5.55 | 8.26 | 20 | 8.96 | |
| PTB ratio | 5.5 | 5.55 | 8.26 | 20 | 8.96 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -42.09 | -25.45 | -40.18 | -77.12 | -104.77 | |
| EV to operating cash flow | -39.9 | -29.31 | -45.32 | -79.35 | -114.61 | |
| EV to free cash flow | -39.81 | -29.3 | -45.27 | -79.3 | -114.3 | |
| Earnings yield | -0.03 | -0.03 | -0.03 | -0.01 | -0.01 | |
| Free cash flow yield | -0.02 | -0.03 | -0.02 | -0.01 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 9.8 | 5.84 | 6.16 | 4.36 | 13.4 | |
| Current ratio | 11.01 | 9.34 | 6.82 | 7.23 | 22.14 | |
| Interest coverage | -14.95 | 17.18 | 0 | 0 | 0 | |
| Income quality | 0.73 | 0.94 | 0.64 | 1.02 | 0.92 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -2 | -0.48 | -0.85 | -0.61 | -0.25 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.97 | 5.37 | 5.41 | 4.4 | 6.13 | |
| ROIC | -0.11 | -0.17 | -0.25 | -0.23 | -0.08 | |
| Return on tangible assets | -0.14 | -0.15 | -0.21 | -0.2 | -0.07 | |
| Graham Net | 3.05 | 2.58 | 2.14 | 1.76 | 4.56 | |
| Working capital | 413.16M | 361.04M | 298.66M | 250.92M | 678.67M | |
| Tangible asset value | 414.68M | 362.49M | 299.87M | 251.81M | 679.34M | |
| Net current asset value | 412.86M | 360.99M | 298.66M | 250.92M | 678.67M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 2.24M | 794.5K | 854K | 1.12M | 1.22M | |
| Average payables | 10.73M | 7.68M | 13.91M | 16.99M | 5.71M | |
| Average inventory | 0 | 0 | 0 | 0 | 0.5 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 3.78K | 357.1 | 6.94K | 1.94K | 6.07K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.02 | 0.25 | 0.01 | 0.05 | 0.01 | |
| Inventory turnover | 0 | 5858335.39B | 0 | 0 | 58K | |
| ROE | -0.15 | -0.16 | -0.25 | -0.23 | -0.08 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
IMVT Frequently Asked Questions
What is Immunovant, Inc. stock symbol ?
Immunovant, Inc. is a US stock , located in New york of Ny and trading under the symbol IMVT
What is Immunovant, Inc. stock quote today ?
Immunovant, Inc. stock price is $27.81 today.
Is Immunovant, Inc. stock public?
Yes, Immunovant, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.14M
- Market Capitalization 4.26B
- Employee 164
- CEO Dr. Peter Salzmann M.B.A., M.D.
- Headquarters New York,NY,US
- IPO Date 2019-06-21
-
Website
https://immunovant.com 
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
